The studies mentioned above, including our microglia-specific effects of group I mGluR modulation, are worth considering in the potential therapeutic application of mGluR5-targeted drugs to be exploited for ALS and other neurodegenerative diseases characterized by glial activation and neuroinflammatory features. The gene discussed is GRM5; the disease is amyotrophic lateral sclerosis.